文献速递腹部儿科影像MR

定量MRI指标与儿童及青年自身免疫性肝病临床风险评分的关联

Associations Between Quantitative MRI Metrics and Clinical Risk Scores in Children and Young Adults With Autoimmune Liver Disease.
PubMed 文献 · AJR Am J Roentgenol · 2022-01-26

这项前瞻性研究纳入58例自身免疫性肝病(AILD)儿童及青年,分析肝脏MRI弹性成像、T2*校正T1(cT1)和定量MRCP指标与Mayo风险评分及SCOPE指数的关联。结果显示肝硬度、全肝cT1四分位距(IQR)及胆管直径与两项临床风险评分独立相关,可能作为临床有意义终点的替代标志物。

要点

  • 肝硬度、全肝cT1 IQR及胆管直径与Mayo风险评分和SCOPE指数独立相关。
  • SCOPE指数高于低风险的最佳预测指标为肝硬度(OR=49.6)和胆总管最大直径(OR=2.5)。
  • 多参数定量MRI可能作为儿童AILD的无创诊断和预后工具。

核心结论

  • 在AILD儿童及青年中,肝硬度增高、cT1 IQR增高及胆管直径增大与更高(更差)的Mayo风险评分和SCOPE指数独立相关,可能为临床有意义终点的替代标志物。

研究设计与样本

  • 前瞻性研究,纳入58例AILD患者(35例男性、23例女性;平均年龄15.1±1.1岁,范围6-24岁;其中PSC 16例、自身免疫性肝炎30例、自身免疫性硬化性胆管炎12例),行研究性肝脏MRI检查包括MR弹性成像、T2*校正T1(cT1)和定量MRCP测量;采用Spearman秩相关和多变量回归分析。

关键影像表现/征象

  • 平均肝硬度为2.8±1.1 kPa,全肝平均cT1为874.7±77.7 ms,全肝cT1四分位距(IQR)为150.8±55.6 ms。
  • Mayo风险评分与肝硬度(ρ=0.56;p<.001)、全肝平均cT1(ρ=0.31;p=.02)、全肝cT1 IQR(ρ=0.58;p<.001)及多项定量MRCP指标(ρ=0.36-0.45,p<.001)显著相关。
  • SCOPE指数与肝硬度(ρ=0.68;p<.001)、全肝cT1 IQR(ρ=0.51;p<.001)及多项定量MRCP指标(ρ=0.47-0.49;p<.001)显著相关。

诊断标准与关键数值

  • 多变量线性回归显示肝硬度、全肝cT1 IQR和左肝管最大直径为Mayo风险评分的显著独立预测因子(校正R²=0.45)。
  • 多变量线性回归显示肝硬度、全肝cT1 IQR、胆总管(CBD)最大直径和CBD中位直径为SCOPE指数的显著独立预测因子(校正R²=0.69)。
  • 逻辑回归显示SCOPE指数高于低风险的最佳预测指标为肝硬度(OR=49.6;95%CI 3.1-793.6)和CBD最大直径(OR=2.5;95%CI 1.3-4.7)。

临床应用与阅片要点

  • 阅片时可关注肝硬度、全肝cT1 IQR及胆管直径等定量指标,这些指标与Mayo风险评分和SCOPE指数独立相关。
  • 多参数定量MRI可能作为儿童AILD的无创诊断和预后工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. The Mayo risk score and SCOPE (Sclerosing Cholangitis Outcomes in Pediatrics) index are clinical risk scores for monitoring the progression of primary sclerosing cholangitis (PSC) and predicting clinically important endpoints. OBJECTIVE. The purpose of this study was to evaluate relationships between quantitative MRI measures of liver disease and clinical risk scores in children and young adults with autoimmune liver disease (AILD). METHODS. This prospective study included 58 patients (35 male and 23 female patients; mean age, 15.1 ± 1.1 [SD] years [range, 6-24 years]) with AILD (16 with PSC, 30 with autoimmune hepatitis, and 12 with autoimmune sclerosing cholangitis) who underwent research liver MRI examinations including MR elastography, T2*-corrected T1 (cT1), and quantitative MRCP measurements. Associations between quantitative MRI metrics and clinical risk scores were evaluated using Spearman rank-order correlation coefficients and multivariable regression analyses. RESULTS. The mean Mayo risk score was -1.1 ± 0.9 (SD) (range, -2.9 to 1.1); the mean SCOPE index was 2.7 ± 2.2 (range, 0-9). Mean liver stiffness was 2.8 ± 1.1 kPa, whole-liver mean cT1 was 874.7 ± 77.7 ms, and whole-liver cT1 interquartile range (IQR) was 150.8 ± 55.6 ms. The Mayo risk score was significantly correlated with liver stiffness (ρ = 0.56; p < .001), whole-liver mean cT1 (ρ = 0.31; p = .02), whole-liver cT1 IQR (ρ = 0.58; p < .001), and multiple quantitative MRCP measures (ρ = 0.36-0.45, p < .001). SCOPE index was significantly correlated with liver stiffness (ρ = 0.68; p < .001), whole-liver cT1 IQR (ρ = 0.51; p < .001), and multiple quantitative MRCP measures (ρ = 0.47-0.49; p < .001). Multivariable linear regression analyses identified liver stiffness, whole-liver cT1 IQR, and left hepatic duct maximum diameter as significant independent predictors of the Mayo risk score (adjusted R2 = 0.45), and liver stiffness, whole-liver cT1 IQR, maximum common bile duct (CBD) diameter, and median CBD diameter as significant independent predictors of the SCOPE index (adjusted R2 = 0.69). On logistic regression analysis, greater than low risk by SCOPE index was best predicted by liver stiffness [odds ratio [OR] = 49.6; 95% CI, 3.1-793.6) and maximum CBD diameter (OR = 2.5; 95% CI, 1.3-4.7). CONCLUSION. Increased liver stiffness, increased cT1 IQR, and larger bile duct diameters are independently associated with higher (worse) Mayo risk score and SCOPE index among children and young adults with AILD and may be surrogate markers of clinically meaningful endpoints. CLINICAL IMPACT. Multiparametric MRI of the liver incorporating quantitative metrics may serve as a noninvasive diagnostic and prognostic tool in pediatric AILD. TRIAL REGISTRATION. ClinicalTrials.gov: NCT03175471.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. McCrary, Trout, Mahalingam, et al. Associations Between Quantitative MRI Metrics and Clinical Risk Scores in Children and Young Adults With Autoimmune Liver Disease. AJR Am J Roentgenol. 2022. PMID: 35080454. doi:10.2214/AJR.21.27204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。